Click below to read more about each of our Clinical Trials to date
Immunogenecity and Safety of GBS-NN/NN2 in Older Adults
Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
Group B Streptococcus Vaccine in Healthy Females
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age
Fischer et al. Vaccine 2021. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
Pawlowski et al. Cell Rep Med 2022. A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains.
Correlates of Protection
Dangor et al. Vaccine 2023. Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.